PAK1 and glioblastoma: Through WB experiments, we found that PAK1 and AKT1 inhibitors both significantly reduced phosphorylated (p)-PAK1 and p-AKT1 levels in GBM cells (Fig. 7E, Additional file 23: Figure S21E), while the protein and mRNA levels of PAK1 and AKT1 were not significantly altered (Fig. 7E, Additional file 23: Figure S21C–E).